Watch TNGX. Know when insiders buy.
One email the day a filing lands. Free.
TNGX
Tango Therapeutics, Inc.
26.98
+1.73 +6.85%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · insiders 25, shorts 53
Insiders, 90 days
−$1.5M
net selling · 0 buys, 6 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.5BP/E —DIV YIELD —FCF YIELD -3.17%REV TTM $53.8M +121.5%NET INCOME −$123.7MNET CASH —52W 7.49 – 32.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$59.8M | −$55.3M | — | -0.37 | −$38.9M | −$20K | −$38.8M | Aug 11 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$48.8M | −$45.5M | — | -0.32 | −$44.4M | −$2K | −$44.4M | Aug 11 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$41.9M | −$38.7M | — | -0.30 | −$29.7M | $222K | −$29.9M | Mar 5 |
| Q3 2025 · Sep 30 | $53.8M | +363.6% | — | $14.1M | $15.9M | — | 0.13 | −$31M | $151K | −$31.1M | Nov 4 |
| Q2 2025 · Jun 30 | $3.2M | −84.0% | — | −$41M | −$38.9M | — | -0.35 | −$36.5M | $624K | −$37.1M | Aug 11 |
| Q1 2025 · Mar 31 | $5.4M | −16.7% | — | −$42.5M | −$39.9M | — | -0.36 | −$41.7M | $51K | −$41.7M | Aug 11 |
| Q4 2024 · Dec 31derived | $4.1M | −24.2% | — | −$40.9M | −$37.7M | — | -0.34 | −$36.6M | $124K | −$36.8M | Mar 5 |
| Q3 2024 · Sep 30 | $11.6M | +8.2% | — | −$32.9M | −$29.2M | — | -0.27 | −$33.4M | $115K | −$33.5M | Nov 4 |
| Q2 2024 · Jun 30 | $19.9M | — | — | −$29.6M | −$25.6M | — | -0.24 | −$23.6M | $320K | −$23.9M | Nov 4 |
| Q1 2024 · Mar 31 | $6.5M | — | — | −$42.3M | −$37.9M | — | -0.35 | −$37.9M | $195K | −$38.1M | Nov 4 |
| Q4 2023 · Dec 31derived | $5.4M | — | — | −$35M | −$30.8M | — | -0.30 | −$27.5M | $226K | −$27.7M | Mar 5 |
| Q3 2023 · Sep 30 | $10.7M | — | — | −$25.6M | −$22.3M | — | -0.23 | −$31.1M | $16K | −$31.2M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $62.4M | — | −$111.3M | −$101.6M | -162.9% | -0.87 | −$138.9M | $1M | −$139.9M | — | — |
| FY2024 · to Dec 31 | $42.1M | — | −$145.6M | −$130.3M | -309.7% | -1.19 | −$131.5M | $754K | −$132.3M | — | — |
| FY2023 · to Dec 31 | $36.5M | — | −$114.2M | −$101.7M | -278.5% | -1.08 | −$118M | $1.5M | −$119.5M | — | — |
| FY2022 · to Dec 31 | $24.9M | — | −$111.1M | −$108.2M | -435.1% | -1.23 | −$109.1M | $7.7M | −$116.8M | — | — |
| FY2021 · to Dec 31 | $37M | — | −$58.2M | −$58.2M | -157.2% | -0.94 | −$59.5M | $1.8M | −$61.4M | — | — |
| FY2020 · to Dec 31 | $7.7M | — | −$52.2M | −$52M | -678.8% | -1.63 | $70.1M | $1.1M | $69M | — | — |
Every number comes from Tango Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.